Favorable overall survival in stage III melanoma patients after adjuvant dendritic cell vaccination

Kalijn F. Bol, Erik H.J.G. Aarntzen, Florentien E.M. in ’t Hout, Gerty Schreibelt, Jeroen H.A. Creemers, W. Joost Lesterhuis, Winald R. Gerritsen, Dirk J. Grunhagen, Cornelis Verhoef, Cornelis J.A. Punt, Johannes J. Bonenkamp, Johannes H.W. de Wilt, Carl G. Figdor, I. Jolanda M. de Vries

Research output: Contribution to journalArticle

Abstract

Melanoma patients with regional metastatic disease are at high risk for recurrence and metastatic disease, despite radical lymph node dissection (RLND). We investigated the immunologic response and clinical outcome to adjuvant dendritic cell (DC) vaccination in melanoma patients with regional metastatic disease who underwent RLND with curative intent. In this retrospective study, 78 melanoma patients with regional lymph node metastasis who underwent RLND received autologous DCs loaded with gp100 and tyrosinase and were analyzed for functional tumor-specific T cell responses in skin-test infiltrating lymphocytes. The study shows that adjuvant DC vaccination in melanoma patients with regional lymph node metastasis is safe and induced functional tumor-specific T cell responses in 71% of the patients. The presence of functional tumor-specific T cells was correlated with a better 2-year overall survival (OS) rate. OS was significantly higher after adjuvant DC vaccination compared to 209 matched controls who underwent RLND without adjuvant DC vaccination, 63.6 mo vs. 31.0 mo (p = 0.018; hazard ratio 0.59; 95%CI 0.42–0.84). Five-year survival rate increased from 38% to 53% (p < 0.01). In summary, in melanoma patients with regional metastatic disease, who are at high risk for recurrence and metastatic disease after RLND, adjuvant DC vaccination is well tolerated. It induced functional tumor-specific immune responses in the majority of patients and these were related to clinical outcome. OS was significantly higher compared to matched controls. A randomized clinical trial is needed to prospectively validate the efficacy of DC vaccination in the adjuvant setting.

Original languageEnglish (US)
JournalOncoImmunology
Volume5
Issue number1
DOIs
StatePublished - Jan 1 2016

    Fingerprint

Keywords

  • Adjuvant therapy
  • Dendritic cell
  • Immunotherapy
  • Melanoma
  • Vaccination

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Cite this

Bol, K. F., Aarntzen, E. H. J. G., in ’t Hout, F. E. M., Schreibelt, G., Creemers, J. H. A., Lesterhuis, W. J., Gerritsen, W. R., Grunhagen, D. J., Verhoef, C., Punt, C. J. A., Bonenkamp, J. J., de Wilt, J. H. W., Figdor, C. G., & de Vries, I. J. M. (2016). Favorable overall survival in stage III melanoma patients after adjuvant dendritic cell vaccination. OncoImmunology, 5(1). https://doi.org/10.1080/2162402X.2015.1057673